Linagliptin 2.5 mg Twice Daily Versus 5 mg Once Daily as add-on Therapy to Twice Daily Metformin in Type 2 Diabetes
Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
The objective of the study is to investigate the efficacy and safety of linagliptin 2.5 mg
twice daily compared to 5 mg once daily compared to placebo given orally for 12 weeks as
add-on therapy to metformin in patients with type 2 diabetes mellitus with insufficient
glycaemic control. It is planned to show non-inferiority of linagliptin 2.5 mg twice daily
compared to 5 mg once daily and each treatment's superiority over placebo.